Brief: SynAct Says CTA Approves For Phase 2B Study Expand
25/08/2022 06:07
Aug 25 (Reuters) - SynAct Pharma AB SYNACT.ST :
* CTA APPROVED FOR THE PHASE 2B STUDY EXPAND
Source text for Eikon: ID:nMFNb31DCq
Further company coverage: SYNACT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development